Primary Open Angle Glaucoma Clinical Trial
Official title:
Magneto Therapy in the Therapy of Glaucoma
Glaucoma is among the leading causes for blindness in the western world. Elevated intraocular pressure (IOP) has been identified as the most important risk factor. However, some patients progress despite adequate IOP lowering while some subjects with elevated IOP never develop glaucoma. Other patients develop glaucoma although IOP measurements were always in the normal range. Therefore, other factors must be involved. In the last years, studies using MRI have been performed and evidence has accumulated that also changes in retrobulbar structures are present, in particular in the lateral geniculate nucleus and the visual cortex. However, these studies were limited by the low spatial resolution of the MRI instruments used.
The two principal pathophysiological mechanisms of glaucomatous process (hydromechanical and
metabolic) determine the development of two trends in the treatment of glaucoma. One
treatment modality is aimed at reduction of intraocular pressure, the other at therapy of
hemodynamic and metabolic disorders. General and local drug therapy and physiotherapy,
including electro- and laser stimulation of the retina and optic nerve and magneto-therapy,
are used to correct these disorders. Modern ocular hypotensive agents are myotics and
beta-adrenoblockers, adrenergic drugs, alpha 2-agonists, carboanhydrase inhibitors, some
prostaglandins, osmotic agents. The progress attained in conservative therapy of glaucoma
should by no means be overstated. In many cases only a combination of conservative and
surgical methods of treatment helps preserve vision in a glaucoma patient.
During the following investigation we will demonstrate that the use of Magneto therapy
Ocular (MTO) reverses the symptomatology in Glaucoma patients. The use of Eyeglass magnetic
prevents the development of Glaucoma disease.During the following investigation we will
demonstrate that the use of MTO reverses the symptomatology of Glaucoma patients; the use of
seawater as drops prevents the development of Glaucoma disease and the combined use of MTO
and seawater is an effective therapy against Glaucoma disease that will cure a grand
percentage of the patients.
We will randomized 100 glaucoma patients and will treat them with MTO (group 1) and seawater
drop (group 2) and combined group 3 and will compare results
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05564091 -
Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma
|
N/A | |
| Recruiting |
NCT02792803 -
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
|
Phase 4 | |
| Terminated |
NCT02801617 -
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Completed |
NCT01384149 -
EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA
|
Phase 1 | |
| Completed |
NCT00300079 -
Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension
|
Phase 4 | |
| Enrolling by invitation |
NCT00221923 -
African Descent and Glaucoma Evaluation Study
|
||
| Recruiting |
NCT05605743 -
Alternate Nostril Breathing Training in Geriatrics With Glaucoma and High Blood Pressure
|
N/A | |
| Completed |
NCT04828057 -
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
|
||
| Completed |
NCT01442896 -
STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk
|
||
| Enrolling by invitation |
NCT05557721 -
Uddevalla Skövde Transscleral Micropulse Study
|
||
| Recruiting |
NCT04595227 -
Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device
|
||
| Terminated |
NCT04141865 -
Effect of Xen Implantation on the Aqueous Humor Proteome
|
||
| Completed |
NCT01943721 -
A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension
|
Phase 1 | |
| Completed |
NCT01979913 -
An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More
|
Phase 4 | |
| Completed |
NCT02023242 -
Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes
|
N/A | |
| Completed |
NCT01769521 -
Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG
|
N/A | |
| Not yet recruiting |
NCT01711177 -
Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
|
N/A | |
| Recruiting |
NCT00773877 -
Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients
|
N/A | |
| Recruiting |
NCT00773123 -
Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.
|
N/A | |
| Completed |
NCT02544646 -
Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG
|
N/A |